2012-09-03 00:25:47 - Adoption of Health Technology Assessments (HTA) Optimizes Drug Pricing and Accelerates Reimbursement Decision-Making

GBI Research, leading business intelligence provider has released its latest research report, entitled "Pharmaceutical Pricing and Reimbursement - ". The report provides a comprehensive overview of the healthcare system and pricing and reimbursement process in the US, top five countries of Europe (the UK, Germany, France, Spain and Italy), Japan, Australia and China, with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes the major changes in pharmaceutical pricing and reimbursement in these nations in the recent past and their impact in the near future.


Full Report Details at
- www.fastmr.com/prod/455915_pharmaceutical_pricing_and_reimbursem ..


Pricing and reimbursement issues are geography-specific and mostly depend upon the economic conditions of the country in question. Governments in the different countries

of Europe have been adopting various measures to bring uniformity to the prices of pharmaceuticals by introducing measures such as international price referencing, pharmacoeconomic evaluations, value-based pricing, internal price referencing, price capping, risk sharing models, and positive and negative price lists. The Value Based Pricing System (VBPS), which is in the process of being adopted by the UK, will only reimburse drugs that provide value to patients. In addition, there are issues with respect to orphan drugs since there are no specific regulations governing their pricing, and pharmaceutical companies are exploiting patients by aggressively pricing these therapeutics. Pricing and reimbursement affects many players in the economic environment such as political parties, pharmaceutical companies, regulatory authorities, and patients. This report analyzes the impact of pricing and reimbursement issues on the concerned stakeholders. The report provides information on the economic situation of different countries with statistical graphs and graphs that represent the expenditure made by respective governments with respect to GDP. The report also provides information on the different pricing and reimbursement mechanisms that are being used in the current environment.

Scope

* A detailed study of the healthcare systems and roles of the key players in the respective pharmaceutical systems in the US, top five countries of Europe (the UK, Germany, France, Spain and Italy), Japan, Australia and China.
* Analysis of the major pricing and reimbursement mechanisms in each country.
* Key trends that have emerged from the recent changes brought about in pricing and reimbursement mechanisms.
* Possible major challenges brought about by the enactment of changes in the pricing and reimbursement scenes in the countries covered.

Reasons to buy

* Build an understanding of the key pricing and reimbursement mechanisms for pharmaceuticals in the key markets of Europe.
* Optimize your investment through the identification and understanding of the changes in the regulatory mechanisms for pharmaceuticals in the economies covered.
* Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene for the countries covered.

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceutical Pricing and Reimbursement - Introduction
3 Pharmaceutical Pricing and Reimbursement - Global Economic Issues
3.1 Trend in Global Pricing and Reimbursement Regime
3.2 Trend Analysis of Healthcare Expenditure Per Capita
3.3 Public Health Expenditure as a Percentage of Total Health Expenditure
3.4 Out-of-Pocket Health Expenditure as a Percentage of Private Expenditure on Health
3.5 Healthy Life Years beyond the Age of 65
4 Pharmaceutical Pricing and Reimbursement - Global Issues
4.1 Reference Prices
4.2 International Price Referencing Adopted to Contain Healthcare Expenditure
4.3 Pharmaceutical Price Capping to Encourage the Use of Generic Drugs
4.4 Positive and Negative Price Formulary to Provide More Clarity on Drugs Covered by Health Insurance
4.5 Value-Based Pricing Systems and Risk-Sharing Models Evaluate Drugs Based on Value and Not Cost
4.6 Single Pricing Strategy in the European Union is a Debatable Issue
4.7 Faster Pricing and Reimbursement Decisions Ensure Quicker Medicine Access and Return on Investments
4.8 Issues in Pricing and Reimbursement in Orphan Drugs
4.9 Difficulty in Economic Evaluation of Orphan Drugs
5 Pharmaceutical Pricing and Reimbursement - Pricing and Reimbursement by Geography
5.1 The US
5.1.1 Macroeconomic Factors (PEST Analysis)
5.1.2 Healthcare System in the Country
5.1.3 Healthcare Expenditure as a Percentage of GDP
5.1.4 Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure
5.1.5 Drug Pricing and Reimbursement Authorities
5.1.6 Issues in Pricing and Reimbursement
6 Top Five Countries of Europe
6.1 Proposal to Speed Up Pricing and Reimbursement Decisions in Europe
6.2 The UK
6.2.1 Macroeconomic Factors (PEST Analysis)
6.2.2 Healthcare System in the Country
6.2.3 Healthcare Expenditure as a Percentage of GDP
6.2.4 Private and Government Expenditure on Healthcare as a Percentage of Total Healthcare Expenditure
6.2.5 Drug Pricing and Reimbursement Authorities
6.2.6 Trends in Pricing and Reimbursement
6.3 France
6.3.1 Macroeconomic Factors (PEST Analysis)
6.3.2 Healthcare System in the Country
6.3.3 Total Expenditure on Healthcare as a Percentage of GDP

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=455915&dt=t

About GBI Research

GBI Research provides industry-leading global business intelligence solutions. Their products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports each year across a wide range of industries. These reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from their expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia. View more research from GBI Research at www.fastmr.com/catalog/publishers.aspx?pubid=1016

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.